00:33 , Sep 28, 2018 |  BC Innovations  |  Targets & Mechanisms

Cell metabolism’s migration

As cancer metabolism undergoes a renaissance in the clinic, with compounds targeting growth factor and nutrient sensing pathways, basic research on metabolic processes in all cells is shining light on pathways that could yield new...
15:18 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting GLS could enhance the efficacy of radiation or reactive oxygen species (ROS)-inducing drugs in IDH1-mutant glioma. In a human glioma cell line expressing mutant IDH1,...
17:39 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Calithera reports Phase I data for CB-839 combo in solid tumors

Calithera Biosciences Inc. (NASDAQ:CALA) reported data from 16 evaluable patients with advanced solid tumors in the Phase I portion of a Phase I/II trial showing that twice-daily 400-800 mg doses of oral CB-839 plus Xeloda...
23:54 , Apr 26, 2018 |  BC Innovations  |  Targets & Mechanisms

Raising metabolism

In the wake of the failure of ECHO-301, drug developers are asking whether the trial design or the target is at fault. But while the value of IDO1 as a target is still in doubt,...
19:02 , Nov 27, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Cell culture and mouse studies suggest the GLS inhibitor CB-839 could help treat KRAS-mutant lung cancers that also harbor KEAP1 mutations. In a mouse model of KRAS- and KEAP1-mutant lung cancer, the...
18:00 , Aug 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Cognitive dysfunction; neurology Mouse and pig studies identified a GLS inhibitor prodrug that could help treat HIV-associated neurocognitive disorders. In a mouse model of HIV-associated neurocognitive dysfunction, the GLS inhibitor 6-diazo-5-oxo-L-norleucine (DON) increased spatial...
23:10 , Mar 22, 2017 |  BC Extra  |  Financial News

RegenxBio, Adaptimmune, Calithera price follow-ons

RegenxBio Inc. (NASDAQ:RGNX), Adaptimmune Therapeutics plc (NASDAQ:ADAP) and Calithera Biosciences Inc. (NASDAQ:CALA) each priced follow-on offerings, raising a total of $206 million. Gene therapy play RegenxBio raised $75.9 million through the sale of 3.7 million...
22:29 , Jan 6, 2017 |  BC Week In Review  |  Clinical News

CB-839: Updated Ph I CX-839-001 data

Updated data from a cohort of 16 evaluable patients with metastatic triple-negative breast cancer (TNBC) in the open-label, dose-escalation U.S. Phase I CX-839-001 trial showed that twice-daily 600 and 800 mg oral CB-839 plus paclitaxel...
21:48 , Dec 2, 2016 |  BC Week In Review  |  Clinical News

CB-839: Updated Ph I data

Updated data from a cohort of 15 evaluable patients with renal cell carcinoma (RCC) in the open-label, dose-escalation, U.S. Phase I CX-839-001 trial showed that 400-800 mg CB-839 twice daily plus 10 mg oral Afinitor...
07:00 , Oct 6, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glutaminase (GLS)

Cancer INDICATION: Pancreatic cancer Mouse studies suggest combining metformin and GLS inhibitor-loaded nanoparticles could help treat pancreatic cancer. In a patient-derived xenograft mouse model of pancreatic cancer, the GLS inhibitor CB-839 or a GLS inhibitor...